Justin Zelin
Stock Analyst at BTIG
(1.94)
# 3,774
Out of 5,182 analysts
40
Total ratings
32.56%
Success rate
-2.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Maintains: Buy | $6 → $9 | $6.96 | +29.31% | 2 | Jan 23, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $45 | $30.04 | +49.80% | 1 | Dec 10, 2025 | |
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $56 | $21.11 | +165.28% | 5 | Dec 9, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Buy | $50 | $23.00 | +117.39% | 1 | Nov 10, 2025 | |
| TCRX TScan Therapeutics | Downgrades: Neutral | n/a | $1.26 | - | 2 | Nov 4, 2025 | |
| IPHA Innate Pharma | Reiterates: Buy | $8 | $1.40 | +471.43% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $62 | $29.04 | +113.50% | 3 | Oct 21, 2025 | |
| CAN Canaan | Reiterates: Buy | $8 | $0.49 | +1,540.35% | 1 | Oct 14, 2025 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $125 | $32.39 | +285.92% | 5 | Sep 22, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $20 → $7 | $0.93 | +652.93% | 3 | Sep 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $5.46 | +266.30% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $42.98 | -2.28% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $0.75 | +106,000.80% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $28.79 | +216.08% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $160 | $7.67 | +1,986.05% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $1.83 | +774.32% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $23.56 | +282.00% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $8.83 | +251.08% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $41.17 | -62.35% | 1 | Mar 28, 2023 |
ImmunityBio
Jan 23, 2026
Maintains: Buy
Price Target: $6 → $9
Current: $6.96
Upside: +29.31%
ArriVent BioPharma
Dec 10, 2025
Initiates: Buy
Price Target: $45
Current: $30.04
Upside: +49.80%
Syndax Pharmaceuticals
Dec 9, 2025
Reiterates: Buy
Price Target: $56
Current: $21.11
Upside: +165.28%
Ascentage Pharma Group International
Nov 10, 2025
Initiates: Buy
Price Target: $50
Current: $23.00
Upside: +117.39%
TScan Therapeutics
Nov 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.26
Upside: -
Innate Pharma
Oct 29, 2025
Reiterates: Buy
Price Target: $8
Current: $1.40
Upside: +471.43%
IDEAYA Biosciences
Oct 21, 2025
Reiterates: Buy
Price Target: $62
Current: $29.04
Upside: +113.50%
Canaan
Oct 14, 2025
Reiterates: Buy
Price Target: $8
Current: $0.49
Upside: +1,540.35%
Viking Therapeutics
Sep 22, 2025
Reiterates: Buy
Price Target: $125
Current: $32.39
Upside: +285.92%
Jasper Therapeutics
Sep 22, 2025
Maintains: Buy
Price Target: $20 → $7
Current: $0.93
Upside: +652.93%
Sep 9, 2025
Reiterates: Buy
Price Target: $20
Current: $5.46
Upside: +266.30%
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $42.98
Upside: -2.28%
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $0.75
Upside: +106,000.80%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $28.79
Upside: +216.08%
Aug 10, 2023
Maintains: Buy
Price Target: $320 → $160
Current: $7.67
Upside: +1,986.05%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $1.83
Upside: +774.32%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $23.56
Upside: +282.00%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $8.83
Upside: +251.08%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $41.17
Upside: -62.35%